Ken Eliasson

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Ofri Mosenzon, Thalia Marie Blicher, Signe Rosenlund et al. · The Lancet Diabetes & Endocrinology · 2019 · 317 citations · Full text

Diabetes Management, Urology, Medicine +11

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 296 citations · Full text

Thrombosis, Dose-finding Phase 2, Cardiovascular Disease +10

Outcome of the Swedish Nationwide Abdominal Aortic Aneurysm Screening Program

Anders Wanhainen, Rebecka Hultgren, Anneli Linné et al. · Circulation · 2016 · 280 citations

Lifestyle and Risk of Screening‐Detected Abdominal Aortic Aneurysm in Men

Otto Stackelberg, Alicja Wolk, Ken Eliasson et al. · Journal of the American Heart Association · 2017 · 59 citations · Full text